Skip to main content
TipRanks
Go Ultimate75% OFF

Sinopharm Group Co (SHTDY) AI Stock Analysis

21 Followers
SHTDY

Sinopharm Group Co

(Other OTC:SHTDY)

Select Model
Rating:75Outperform
Price Target:$12.00â–²(11.63% Upside)
Action:reiterated
Date:11/07/26

Strong valuation and resilient cash-backed profitability support the score, while revenue and margin declines, higher leverage, and overbought technical indicators limit upside.

Positive Factors
Nationwide healthcare distribution networkThe nationwide distribution network gives Sinopharm broad access to institutional and retail healthcare customers. Its coverage across hospitals, clinics, pharmacies and providers supports recurring product flow and creates a durable platform for distributing medicines, devices and consumables at scale.
Negative Factors
Recent revenue contractionRecent revenue contraction marks a deterioration from the stronger growth seen during 2021–2023. If weaker sales persist, the company may have less operating leverage and reduced capacity to absorb distribution costs, while slower volume growth could limit improvement in earnings over the next several quarters.

Sinopharm Group Co (SHTDY) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%SHTDY-15.46%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$6.69B
Dividend Yield
4.67%
Average Volume (3M)
155.02K
Price to Earnings (P/E)
6.4
Beta (1Y)
-0.02
Revenue Growth
2.49%
EPS Growth
7.42%
Country
US
Employees
94,910
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

Sinopharm Group Co Business Overview & Revenue Model

Company Description

Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are org...

How the Company Makes Money

Sinopharm Group generally makes money through: (1) Pharmaceutical and healthcare product distribution: The core revenue stream is selling pharmaceuticals and other healthcare products (including medicines, medical devices, and consumables) to institu...

Sinopharm Group Co Financial Statement Overview

Summary

Resilient profitability and cash conversion support the score, but declining revenue, shrinking gross margins, rising leverage, lower ROE, and weaker recent free-cash-flow growth are meaningful risks.

Income Statement

72Positive

Balance Sheet

68Positive

Cash Flow

75Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue563.46B559.50B584.51B596.57B552.15B521.05B
Gross Profit39.34B40.09B44.26B48.51B47.43B44.05B
EBITDA21.29B20.50B22.55B26.90B26.25B24.68B
Net Income6.99B6.96B7.05B9.05B8.53B7.76B
Balance Sheet
Total Assets404.57B390.61B392.83B383.39B364.78B335.41B
Cash, Cash Equivalents and Short-Term Investments41.90B61.60B54.31B63.81B55.22B43.54B
Total Debt81.32B108.65B76.39B73.78B69.59B68.37B
Total Liabilities268.18B256.36B266.14B263.08B254.71B235.76B
Stockholders Equity85.22B84.01B78.88B74.58B68.07B61.89B
Cash Flow
Free Cash Flow20.67B12.52B9.58B14.84B18.55B7.05B
Operating Cash Flow22.20B14.14B11.55B17.17B20.96B9.31B
Investing Cash Flow-552.41M-963.89M-3.75B-944.53M-3.59B-1.27B
Financing Cash Flow-27.38B-18.69B-17.29B-7.64B-5.69B-14.69B

Sinopharm Group Co Technical Analysis

Technical Analysis SentimentPositive
Last Price10.75

Price Trends

50DMA9.97Positive
100DMA10.32Positive
200DMA11.11Negative

Market Momentum

MACD0.24Positive
RSI61.87Neutral
STOCH32.07Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SHTDY, the sentiment is Positive. The current price of 10.75 is above the 20-day moving average (MA) of 10.48, above the 50-day MA of 9.97, and below the 200-day MA of 11.11, indicating a neutral trend. The MACD of 0.24 indicates Positive momentum. The RSI at 61.87 is Neutral, neither overbought nor oversold. The STOCH value of 32.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SHTDY.

Sinopharm Group Co Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SHTDY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SHTDYSHTDY75Outperform$6.71B6.378.33%4.67%2.49%7.42%
CAHCAH73Outperform$64.54B36.22-62.56%0.74%10.00%16.74%
HSICHSIC65Neutral$9.17B22.6113.13%―6.15%15.68%
CORCOR64Neutral$66.90B19.54115.76%0.70%5.00%124.34%
MCKMCK64Neutral$126.04B27.88-161.18%0.31%8.19%21.01%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
YIYI40Underperform$24.32M-1.5323.64%―-23.90%-45.45%

* Healthcare Sector Average

Performance Comparison

0%50%100%SHTDYCORCAHHSICMCKYIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SHTDY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SHTDYSinopharm Group Co., Ltd. Unsponsored ADR Class H10.75-1.84-14.59%
CORCencora, Inc.350.56-7.35-2.05%
CAHCardinal Health279.2573.6735.84%
HSICHenry Schein82.9412.3417.48%
MCKMcKesson Corporation1091.67242.5428.56%
YI111, Inc.2.77-1.03-27.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026